N/A N=23 Examining a Wheelchair Exercise-training Intervention for Persons With Multiple Sclerosis
Multiple Sclerosis
Primary: Study Feasibility: Number of Participants Recruited — 24 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=137 Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis
Non-radiographic Axial Spondyloarthritis
Primary: Assessment of SpondyloArthritis International Society 40 (ASAS40) Response Rate in TNF-alpha-inhibitor-naive Participants at Week 16 — 58.72; 26.03 Percentage of…
N/A N=247 Biolinq Safety and Effectiveness Trial
Diabetes · Diabetes Mellitus
Primary: In Target Color Indicator - Blue — 7494 Paired Samples - YSI to Biolinq
Phase 2 N=6 A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
Advanced Melanoma
Primary: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After Randomization — 7.9; 8.3 months — p=0.3284
N/A N=32 Hypnotherapy With Audiofiles for Children and Adolescents With Disorders of Gut-brain Interactions in Sweden -a Feasibility Study
Self-hypnosis · Functional Bowel Disorder · Functional Abdominal Pain Syndrome
Primary: Peds-QL-gastro — 49.91; 60.15 units on a scale
Phase 1 N=59 Safety and Immunogenicity of CJCV2 With and Without ALFQ
Campylobacter Infection
Primary: Number and Percentage of Participants With Solicited Local Adverse Events (AEs) Through 7 Days After Each Study Vaccination — 4; 9; 2; 10 Participants
N/A N=551 Evaluation of an Automated Physician-Directed Messaging on Patient Engagement in the Digital Diabetes Prevention Program
Pre Diabetes
Primary: Change in Hemoglobin A1c (HbA1c) Level (mmol/Mol) — 0.02; -0.03 mmol/mol
N/A N=62 The Use of Alloderm Versus Dermacell in Immediate Implant Based Breast Reconstruction
Breast Reconstruction
Primary: Postoperative Duration of Drain Placements — 9.2; 10.8 days — p=0.15
Phase 4 N=50 BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF
Heart Failure With Preserved Ejection Fraction · Hypertension
Primary: Difference in Home Systolic Blood Pressure — 130.7; 134.5 mm Hg — p=0.017
N/A N=236 MIND: Artemis in the Removal of Intracerebral Hemorrhage
Cerebral Hemorrhage · Brain Hemorrhage · Cerebral Parenchymal Hemorrhage
Primary: Global Disability (Functional Outcome) Assessed Via the Ordinal Modified Rankin Score (mRS) — 32; 20; 4; 2 Participants
Phase 4 N=93 The Ultrasound Guided Pericapsular Nerve Group and Anterior Quadratus Lumborum Blocks in Hip Replacement Surgeries
Post Operative Analgesia
Primary: The Total Amount of Morphine Consumption — 6.0; 8.0; 12.0 mg of IV morphine — p=0.035
N/A N=23 Improving Aphasia Using Electrical Brain Stimulation
Stroke · Aphasia
Primary: Language Specific Attention Treatment Probe — 56; 47; 64; 52 Percent
N/A N=23 Continuous Glucose Monitoring in Prediabetes
Pre-diabetes
Primary: Change in Mean Glucose (mg/dL) From Baseline — 2.1 mg/dL — p=0.8
N/A N=18 Implementation Outcome Assessments of the Emergency Department Delirium Screening and Detection Program
Delirium
Primary: Accurate Delirium Screening by Emergency Department (ED) Nurses (RE-AIM: Efficacy) — 4; 1; 8 Site nurses who received Spot Check Form
N/A N=24 Evaluation of the Accuracy of the Hemochron Signature Elite Point of Care Device Compared With Laboratory Assay
Blood Coagulation Tests
Primary: The International Normalised Ratio (INR) Will be Measured by the Laboratory Assay and the Hemochron Signature Elite Device. — 23 Participants